CVS Affirms Wall Street’s 2022 Earnings Views; Shares Rise
(Bloomberg) -- CVS Health Corp.'s initial 2022 earnings outlook matches Wall Street's expectations, Chief Financial Officer Shawn Guertin said Tuesday on a call with analysts.Â
At this point, analysts' average expectation for adjusted profit of $8.20 a share falls within the company's current thinking, Guertin said. CVS plans to provide more details at its December investor day, he said. The shares rose as much as 4% as of 9:38 a.m. in New York, the most intraday since May.Â
Guertin spoke on the call after CVS said this year's adjusted earnings will rise to a range of $7.90 to $8 a share, a 20-cent increase from its earlier forecast, as third-quarter earnings and sales beat Wall Street's expectations.Â
The company said Covid expenses would pressure its health-care benefits unit for the remainder of the year. While it's extremely difficult to predict the path of the virus, Guertin said, CVS anticipates the costs from Covid testing and care will decrease next year, benefiting the health insurance business.Â
On the retail side, CVS expects tests, shots and virus-related store purchases to decline significantly next year. Together, tests and vaccines are expected to pull in $3 billion in revenue this year.Â
Booster shots and a delta-variant induced surge in coronavirus cases renewed demand for Covid vaccines and virus tests in the third quarter, buoying CVS's retail segment. Those same cases are raising costs of care in the insurance unit, as well as at rival Humana, whose shares fell 7% in premarket trading after a cut in its annual forecast.Â
Quarterly Results
Quarterly adjusted earnings were $1.97 a share, CVS said, beating the average projection of $1.78. Revenue of $73.8 billion surpassed the $70.5 billion consensus.
Revenue at the CVS's health-care benefits segment jumped 9.5% to $20.48 billion thanks to growth in its government insurance business. However, Covid-related costs pushed Aetna's medical-benefit ratio to 85.8%, up from 84%. CVS now expects elevated medical costs in the fourth quarter, the company said in its filing. It previously anticipated modestly elevated expenses.
The drugstore chain will start immunizing children now that the U.S. has authorized Pfizer's vaccine for kids ages 5 to 11. CVS expects vaccinations to slow in the fourth quarter, the company said in a quarterly filing.
The company's pharmacy benefits management unit posted $39.05 billion in revenue, up 9.3% from the year-ago quarter. The company attributed the increase to a rebound in pharmacy claims, growth in its specialty pharmacy and brand inflation.
CVS recorded a $431 million impairment in the quarter for its long-term care business. The charge caused operating income to decrease 5.8% from the year-ago quarter.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.